Video

VIDEO: Mastectomy plus reconstruction has highest complication rates of all early BC treatment options


 

AT SABCS 2015

References

SAN ANTONIO – Mastectomy with reconstruction is the outlier in terms of complication rates and cost among options for local therapy for early breast cancer, according to a large observational study presented at the San Antonio Breast Cancer Symposium.

Complication rates during the first 2 years after diagnosis were roughly twice as high for mastectomy plus reconstruction, compared with lumpectomy with whole breast irradiation. Moreover, average total procedural and complication costs were $23,000 greater for women aged 65 years or younger who opted for mastectomy plus reconstruction than for those who chose lumpectomy plus whole breast irradiation. These fresh insights into the trade-offs involved in local treatment options should prove useful in oncologists’ discussions with newly diagnosed patients, as well as for payers, as Dr. Benjamin D. Smith of University of Texas M.D. Anderson Cancer Center, Houston, explains in an interview.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

bjancin@frontlinemedcom.com

Recommended Reading

No racial disparity in appropriate use of Oncotype DX
MDedge Hematology and Oncology
Racial differences found in neoadjuvant chemo, pCR rates for breast cancer
MDedge Hematology and Oncology
AHA: Older breast cancer patients more likely to die of heart disease than malignancy
MDedge Hematology and Oncology
What’s anticipated at SABCS 2015?
MDedge Hematology and Oncology
Die not yet cast for lymphazurin and methylene blue dye
MDedge Hematology and Oncology
High risk for getting breast cancer linked with low risk of metastasis
MDedge Hematology and Oncology
VIDEO: Win-win with denosumab as adjuvant therapy for post-menopausal breast cancer
MDedge Hematology and Oncology
SABCS: CREATE-X – Capecitabine is efficacious against residual HER2-negative breast cancer
MDedge Hematology and Oncology
VIDEO: Adjuvant capecitabine has role for residual disease after neoadjuvant therapy
MDedge Hematology and Oncology
VIDEO: Triple-negative breast cancer outcomes boosted by adding carboplatin to neoadjuvant chemo
MDedge Hematology and Oncology